Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic correction of familial cardiomyopathy in human engineered cardiac tissues.

European heart journal - 14 Nov 2016

Stillitano Francesca, Turnbull Irene C, Karakikes Ioannis, Nonnenmacher Mathieu, Backeris Peter, Hulot Jean-Sébastien, Kranias Evangelia G, Hajjar Roger J, Costa Kevin D

Abstract excerpt

In this study, we used three-dimensional human engineered cardiac tissue technology to directly show that phospholamban (PLN) R14del mutation impairs cardiac contractility and to demonstrate restoration of contractile properties with targeted genetic correction of this inheritable form of dilated cardiomyopathy.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcium-Binding Proteins
Share to Cardiomyopathies
Share to Cardiomyopathy and Myosin Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PLN gene

Share to Genomics

Share to Mutation

Share to Pluripotent Stem Cells Research

Share to Tissue Engineering and Regenerative Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 27450564
DOI: 10.1093/eurheartj/ehw307
PMCID: PMC6425468

Genes

PLN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic correction of familial cardiomyopathy in human engineered cardiac tissues.PMID 27450564Read ↗

Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.Semantic proximity Read ↗

Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.Semantic proximity Read ↗

Engineered cardiac tissue model of restrictive cardiomyopathy for drug discoverySemantic proximity Read ↗

Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR/Cas9 editing.Semantic proximity Read ↗

Full-length dystrophin deficiency leads to contractile and calcium transient defects in human engineered heart tissuesSemantic proximity Read ↗

Spatiotemporal cell junction assembly in human iPSC-CM models of arrhythmogenic cardiomyopathySemantic proximity Read ↗

Cardiac Applications of CRISPR/AAV-Mediated Precise Genome EditingSemantic proximity Read ↗

Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impactSemantic proximity Read ↗

Dynamic loading of human engineered heart tissue enhances contractile function and drives a desmosome-linked disease phenotype.Semantic proximity Read ↗

Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue EngineeringSemantic proximity Read ↗

PLN-L31A/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations.Semantic proximity Read ↗

Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.